Introduction
The introduction of new immunosuppressant drugs in recent years has allowed for a reduction in acute rejection rates paralleled by a highly significant improvement in short-term kidney graft survival. Yet, this improvement has not translated into significant changes in chronic graft loss [261, 262] , and hence, late graft failure continues to be a frequent cause of readmission onto dialysis programs and re-entry onto the waiting list.
Acute vascular rejection and chronic rejection, i.e. interstitial fibrosis and tubulus atrophy (IFTA), are the main causes for renal graft failure and loss [263] . IFTA is a clinicopathological entity characterized by fibrosclerosis of the different renal structures leading to progressive decline of renal function after kidney transplantation [264] . Although the molecular mechanisms that underlie the pathophysiology of IFTA remain far from clear, it seems to result from the concerted action of immunological and non-immunological factors [265] . The use of calcineurin inhibitors (CNI) are amongst others identified as a non-immunologic risk factor, associated with nephrotoxic [266] and neurotoxic [267] side effects. Attempts to minimize or wean patients off of CNI have shown that improvement in renal function is often obtainable but only at the expense of increased alloimmune reactions [268] . Developing a calcineurin inhibitor-based long-term maintenance immunosuppressive drug regimen with improved longterm tolerability is therefore a highly desirable endeavor.
In a prospective randomized multicenter trial we have shown that donor treatment with lowdose dopamine has a salutary effect on immediate kidney graft function [45] . In a subgroup analysis this was translated into a better graft survival for recipients who obtained a renal allograft with prolonged cold preservation time. Graft survival was also improved in heart allograft recipients [150] but did not affect outcome after liver transplantation [45] . Based on in vitro experiments, we have postulated that this protective effect is independent of the hemodynamic action of dopamine and requires the redox-active catechol structure [156] .
Moreover we have shown that conjugation of n-octanoic acid to the amine side chain of dopamine, which likely impairs adrenergic and dopaminergic receptor engagement, results in a far more protective compound [162] . N-octanoyl dopamine (NOD) not only protects cells and tissues against prolonged hypothermic preservation, it also strongly inhibits platelet function [269] and activation of NF-κB in vitro and improves acute kidney injury (AKI) in vivo [178] .
In keeping with the notion that NF-κB plays a pivotal role in cellular immunity, in the present study we further investigated the potential benefit of NOD in transplantation medicine by Chapter 7 116 assessing the influence of NOD on T cell activation in vitro. To this end, we tested if NOD inhibits T cell proliferation, how this is accomplished in mechanistic terms and if NOD can decrease CNI concentrations without reducing T cell suppression.
Materials and Methods

Isolation of human PBMC, T cells and T cell subsets
Human peripheral blood mononuclear cells (PBMC) from healthy adult volunteer donors were isolated by centrifugation of venous blood on Ficoll-Hypaque density gradients (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). T cells were enriched from human PBMCs applying Miltenyi Biotec's PAN T cell Isolation kit II according to manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Untouched CD 4 + cells were further purified using positive CD8 + selection (CD8 microbeads) and naive and memory populations were obtained by positive selection with CD45RO microbeads. Purity of more than 98% was controlled by FACS-analysis. T cells or PBMCs were cultured with RPMI 1640 supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, Pasching, Austria) and 1% penicillin and streptomycin (Sigma-Aldrich, Munich, Germany).
N-octanoyl dopamine and N-octanoyl tyramine synthesis
N-octanoyl dopamine (NOD) and N-octanoyl tyramine (NOT) were synthesized from commercially available precursors as previously described [162] . Briefly, octanoic acid was dissolved in tetrahydrofuran and N-ethyldiisopropylamine before conversion to their mixed anhydride by the reaction with ethyl chloroformate. For coupling the crude mixed anhydride and dopamine hydrochloride were dissolved in N,N-dimethylformamide in the presence of diisopropylamine.
Sodium hydrogen carbonate and sodium sulfite were added and after evaporation of the solvent the product was obtained. N-octanoyl tyramine was synthesized according to NOD using the analog mixed anhydride coupled to tyramine as reaction component. Both products were purified by two-fold recrystallization from dichloremethane which was proved by thin layer chromatography. Samples were dissolved in ethanol, investigated by 1 H-NMR spectroscopy (Bruker AC250) and yielded spectra in accordance with the expected structure. Vehicle concentration in cell culture was less than 0.1 ‰ and had no influence on results (vehicle control not shown).
T cell proliferation assay
Human PBMCs (10 6 cells/ml) were cultured in 200 µl of complete medium in 96-well, U-bottom microtiter plates (CELLSTAR-greiner bio-one, Kremsmünster, Austria 
Western blots
Human T cells (10 6 cells/ml) were stimulated for various time intervals with anti-CD3/CD28
Dynabeads (Invitrogen Dynal AS, Oslo, Norway) in the presence or the absence of 100 µM of NOD.
Cells were then washed with PBS and proteins were extracted in 100 µl of lysis buffer (10 mM HEPES (pH 7.9 at 25°C), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 0. 
Nuclear protein extraction and electrophoretic mobility shift assay (EMSA)
Human T cells (10 6 cells/ml) were stimulated for various time intervals with 50 ng/ml PMA and 1 µg/ml ionomycin (Sigma-Aldrich, St. Louis, MO, USA) in the presence or absence of 100 µM NOD.
Nuclear extracts were prepared as previously described [270] and protein concentrations were determined by Bradford assay. NF-κB (5'-AGTTGAGGGGACTTTCCCAGGC-3') or AP-1 (5'-CGCTTGATG ACTCAGCCGGAA-3') double-stranded consensus oligonucleotide (both Promega
Corp., Madison, WI, USA) were end-labeled with γ-32 P-ATP using T4-polynucleotide kinase, ethanol precipitated and finally dissolved in 20 µl of distilled water. 1 µl of 32 P-labeled probe (~30,000 cpm) and 15 μg of nuclear extracts were added to a binding reaction mixture containing: 10 mmol/l HEPES (pH 7.5), 0.5 mmol/l EDTA, 70 mmol/l KCl, 2 mmol/l DTT, 2% glycerol, 0.025% NP-40, 4% Ficoll, 0.1 mol/l PMSF, 1 mg/ml bovine serum albumin and 0.1 mg/ml poly di/dc and incubated for 30 min at room temperature. DNA-protein complexes were separated by electrophoresis through a 5% nondenaturing acrylamide: bis-acrylamide gel in 0.5 × Tris-borate (TBE) /EDTA for 3 h at 220 V. Gels
Chapter 7 120 were analyzed by autoradiography using an Amersham Hyperfilm ECL (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). In each experiment, specificity of binding was demonstrated by preincubation with cold consensus (100x excess of unlabeled oligonucleotides) or mutated NF-κB or AP-1 oligonucleotides to the nuclear extracts. In addition, supershifts were performed by adding p50, p52, p65, RelB, c-Rel, c-jun and c-fos antibodies to the samples (all Santa Cruz Biotechnology, Heidelberg, Germany).
Luminol oxidation assay
To test the anti-oxidant capacity of NOD and NOT the luminol oxidation assay was used. To this end, serial dilutions of NOD or NOT were added to a complete volume of 200 µl of reaction mixture containing 0.005 U horseradish peroxidase (HRP) and 20 µM of luminol. The reaction was immediately recorded in a luminometer (Lumat LB9507, Berthold, Bad Wildbad, Germany) after addition of 0.01% H2O2.
Statistics
Data is expressed as mean ± standard deviation (SD). For proliferation assays, cell cycle analysis, cap formation and ROS measurements statistical analysis were performed using Student's t-test with previous testing of equality of variances (SigmaPlot 11.0, Systat Software GmbH, Erkath, Germany).
If equality test failed the Kruskal-Wallis-test was performed. For western blot average optical densities of bands of all blots were assessed using ImageJ 1.46 and Student's t-test was performed on ratio of cyclin D/β-actin or phosphorylated/total protein as mentioned above. A p-value of less than 0.05 was considered as significant. a.
Results
NOD inhibits T cell activation transiently
b. c.
NOD does not impair early T cell activation events
To evaluate whether the inhibitory effects of NOD on T cell activation was also noticed at the level of early cytokine production, intracellular cytokine staining was performed after 4 h of PMA/ionomycin stimulation. Expression of IL-2, TNF-α and INF-γ was more pronounced in the memory CD45RO population and was not largely affected by NOD (Figure 3a) . It therefore seemed that NOD did not prevent early T cell activation events. To further substantiate this finding cap formation following anti-CD3/CD28 stimulation of purified CD3 + cells was assessed. Cap formation was defined as a clear local enrichment of CD3 on the surface of the cells (Figure 3b ). No significant differences between cells that were stimulated in the presence or absence of NOD were noticed (Figure 3b ). Phosphorylation of the T cell receptor (TCR) signaling proteins ZAP70 and Lck occurred within 5 minutes of anti-CD3/CD28 stimulation and maintained to be phosphorylated over the observation period of 1 h. In line with the notion that NOD did not impair early activation events in T cells, no significant changes in the phosphorylation of ZAP70 or Lck were observed in the presence of NOD (Figure 3c ).
NOD inhibits both NF-B and AP-1 activation
To elucidate if activation of transcription factors NF-B and AP-1 was impaired by NOD, b.
complexes were separated by electrophoresis. Specificity of the bands was assessed by incubation with a 100x excess of unlabeled (cold) consensus and by incubation with specific monoclonal antibodies to induce a supershift (n.s. not specific). A total of three different experiments with essentially the same results were performed.
Requirement of redox activity
Because both NF-B and AP-1 are redox-dependent transcription factors we assessed to what extent redox-active moieties in NOD could account for its effect on T cell activation. To this end we synthesized N-octanoyl tyramin (NOT), which, compared to NOD, lacks one hydroxyl group at the aromatic ring ( Figure 5a ). As indicated in Figure 5b , NOD dose-dependently quenched the chemiluminescence signal that occured as a consequence of peroxidase-mediated oxidation of luminol. In contrast, NOT did not significantly change the chemiluminescence signal over a wide range of different concentration, suggesting that NOT cannot act as reducing agent. Inasmuch as NOT was not able to inhibit T cell proliferation (Figure 5c ) it seemed that the inhibitory effect of NOD was likely mediated via its redox-active catechol structure. To further substantiate that reactive oxygen species (ROS) are generated during T cell activation and to assess if this was influenced by NOD, we measured intracellular ROS production by means of 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) (H2-DCFDA). Upon anti-CD3/CD28 stimulation H2-DCFDA fluorescence intensity increased already after 5 minutes of stimulation and further increased at 20 minutes. In the presence of NOD the increase in fluorescence intensity was significantly inhibited (Figure 5d ). 
Discussion
N-acyl dopamine derivatives (NADD) have gained prominence with the identification that these structures have the propensity to activate the endocannabinoid and endovanilloid systems [271] .
Endogenous NADD, e.g. N-arachidonoyl-, N-oleoyl-, N-palmitoyl-and N-stearoyl dopamines are predominantly found in the brain with the highest levels in the striatum and low levels elsewhere [272] . In contrast to the endogenous NADD, NOD contains a short fatty acid but similar to endogenous NADD activates transient receptor potential vanilloid 1 receptors (TRPV1) [178] . This may at least partially explain the beneficial effect of NOD in ischemiainduced acute kidney injury (AKI) [273, 274] . Apart from the activation of the endocannabinoid and endovanilloid systems it should also be noted that NADD have anti-inflammatory properties [179, 275] and, as such, are gaining interest as potential therapeutics for the treatment of a variety of inflammatory diseases. Since NOD has the ability to inhibit NF-κB activation [178] in the present study we assessed immunosuppressive properties of NOD by studying if NOD is able to suppress T cell activation, and more importantly, if it has synergistic effects with CNI on T cell proliferation. This study reveals the following findings: Firstly, NOD transiently inhibits T cell proliferation in a dose dependent fashion. This was reflected by a decreased percentage of T cells that became CD25 positive or started to express the memory marker CD45RO upon mitogen activation. NOD also caused G1-arrest in cell cycling, which was paralleled by a diminished cyclin D expression. Secondly, the T cell suppressive properties of NOD were most likely depending on the redox-active dopamine moiety, as NOT did not inhibit T cell proliferation. Thirdly, NOD did not affect early TCR signaling, e.g.
phosphorylation of Lck and ZAP70 and CD3 capping. In contrast, activation of the redoxdependent transcription factors NF-κB and AP-1 was profoundly impaired. Last but not least, NOD and CNI display a strong synergy to suppress T cell proliferation.
Activation of the TCR/CD3 complex in T cells leads to the immediate activation of transcription factors that regulate a variety of activation-associated genes, e.g. cytokines and surface receptors. Oligomerisation of the TCR/CD3 complex and subsequent activation of phospholipase C-γ by specific tyrosine kinases at the lipid rafts are believed to be the initiating steps that finally culminate in full T cell activation [276] [277] [278] . We provide three lines of evidence that NOD does not impair these events. Firstly, CD3 cap formation was not prevented by NOD. Hence, the immunoreceptor tyrosine-based activation motif (ITAM) elements in the cytoplasmic tails of the associated CD3 subunits would still be able to couple with critical tyrosine kinase pathways involving Lck and ZAP70 [279] . Secondly, indeed activation of both Lck and ZAP70 was not affected in the presence of NOD and, thirdly, cytokine production within the first 4 hours following T cell stimulation appeared to be normal.
Although NOD did not impair these initial T cell activation events, activation-induced ROS production was significantly inhibited by NOD. Because the redox-inactive NOT neither quenched HRP-mediated luminol oxidation nor inhibited T cell proliferation, it seems that the redox-active moiety of NOD is required for the suppressive effect on T cell proliferation.
Studies performed by Kaminski et al. [280] clearly have demonstrated the importance of mitochondrial-derived ROS for gene expression upon TCR stimulation. TCR-triggered gene expression is controlled by both redox-dependent (NF-B, AP-1) and redox-independent transcription factors (NF-AT, SP-1, Oct-1, or CREB). Activation of NF-B and AP-1 was strongly diminished in the presence of NOD, albeit that the kinetics and degree of inhibition by NOD for each transcription factor was different. This might explain why early cytokine expression, e.g. IL-2, TNF-α and INF-γ, was still observed. Impaired activation of redoxindependent transcription factors in activated T cells has also been reported for other NADD
[192], but was not studied for NOD in our study.
We are aware of the studies performed by Sancho et al. [192, 193] who demonstrate that Noleoyl-and N-arachidonoyl dopamine inhibit proliferation of Jurkat T cells. In contrast to our study they did not observe inhibition of NF-B binding in EMSA. In addition they observed a dose dependent impairment of transcriptional activity of luciferase reporter constructs under the control of the IL-2 or TNF-α promoter. This is also in contrast to our findings that NOD did not affect early IL-2 and TNF-α expression in activated T cells. Whether these differences can be explained by the different cells used in both studies (Jurkat T cells vs. primary T cells or PBMCs) or by the different composition of the NADD (long chain vs. short chain fatty acid) is at present unclear. Other reports also have shown that TRPV1 activation inhibits both early and late events in TCR-mediated T cell activation, e.g. calcium mobilization, NF-AT activation, IL-2 gene transcription, IL-2R expression, and cell-cycle progression [281, 282] . It therefore also remains to be assessed to what extent TRPV1 activation is contributing to the T cell suppressive effect of NOD or NADD in general.
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NOD does not bind to dopaminergic receptors, yet once it is internalized it might be subjected to hydrolysis resulting in dopamine and octanoic acid. This therefore raises the question as to whether NOD mediated inhibition of T cell proliferation is due to the release of dopamine and engagement of dopaminergic receptors. Indeed there is clear evidence that engagement of dopamine (D1 and D2) receptors on T-lymphocytes result in inhibition of T cell proliferation [283] . Yet, in contrast to our present findings this is ZAP70 depended process, in which engagement of these receptors inhibits ZAP70 phophorylation. It is also noteworthy that NADD inhibit proliferation of Jurkat cells [28, 29] while this is not observed for dopamine [284] .
Even though much controversy on the exact mechanism by which NADD inhibit T cell activation remains, endowed with a unique combination of TRPV1 agonistic-, immunosuppressive-, and NF-B-inhibitory properties, these compounds may find a potential use for the treatment of inflammatory condition, e.g. autoimmune diseases or transplant rejection. Although the latter can be successfully treated with CNI, the use of CNI has been identified as risk factor for IFTA. Consequently, immunosuppressive regimens that allow low CNI dosage without an increased risk for transplant loss are increasingly being studied to prevent or delay the rate of chronic transplant loss [285, 286] . 
